Search

Your search keyword '"Ristow, Bryan"' showing total 26 results
Start Over Author "Ristow, Bryan"
26 results on '"Ristow, Bryan"'

1. Relationship of Bisphosphonate Therapy and Atrial Fibrillation/Flutter Outcomes of Sleep Disorders in Older Men (MrOS Sleep) Study

Author

Thadani, Samir R, Ristow, Bryan, Blackwell, Terri, Mehra, Reena, Stone, Katie L, Marcus, Gregory M, Varosy, Paul D, Cummings, Steven R, Cawthon, Peggy M, and Group, Osteoporotic Fractures in Men Study Research

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Aging, Heart Disease, Sleep Research, Cardiovascular, Clinical Research, Aged, Aged, 80 and over, Atrial Fibrillation, Atrial Flutter, Bone Density Conservation Agents, Diphosphonates, Electrocardiography, Humans, Incidence, Logistic Models, Male, Multivariate Analysis, Osteoporosis, Polysomnography, Prevalence, Proportional Hazards Models, Prospective Studies, Risk Factors, Sleep Apnea Syndromes, atrial fibrillation, bisphosphonates, sleep-disordered breathing, Osteoporotic Fractures in Men Study (MrOS) Research Group, Respiratory System, Cardiovascular medicine and haematology, Clinical sciences
Abstract

BackgroundPrior studies suggested an association between bisphosphonates and atrial fibrillation/flutter (AF) in women. This relationship in men, including those with sleep-disordered breathing (SDB), remains unclear. This study evaluated the relationship between bisphosphonate use and prevalent (nocturnal) and incident (clinically relevant) AF in a population of community-dwelling older men.MethodsA total of 2,911 male participants (mean age, 76 years) of the prospective observational Osteoporotic Fractures in Men Study sleep cohort with overnight in-home polysomnography (PSG) constituted the analytic cohort. Nocturnal AF from ECGs during PSG and incident AF events were centrally adjudicated. The association of bisphosphonate use and AF was examined using multivariable-adjusted logistic regression for prevalent AF and Cox proportional hazards regression for incident AF.ResultsA total of 123 (4.2%) men were current bisphosphonate users. Prevalent nocturnal AF was present in 138 participants (4.6%). After multivariable adjustment, there was a significant association between current bisphosphonate use and prevalent AF (OR, 2.33; 95% CI, 1.13-4.79). In the subset of men with moderate to severe SDB, this association was even more pronounced (OR, 3.22; 95% CI, 1.29-8.03). However, the multivariable-adjusted relationship between bisphosphonate use and incident AF did not reach statistical significance (adjusted hazard ratio, 1.53; 95% CI, 0.96-2.45).ConclusionsThese results support an association between bisphosphonate use and prevalent nocturnal AF in community-dwelling older men. The data further suggest that those with moderate to severe SDB may be a particularly vulnerable group susceptible to bisphosphonate-related AF. Similar associations were not seen for bisphosphonate use and clinically relevant incident AF.

Published
2016

24. Elevated Pulmonary Artery Pressure by Doppler Echocardiography Predicts Hospitalization for Heart Failure and Mortality in Ambulatory Stable Coronary Artery Disease The Heart and Soul Study

Author

Ristow, Bryan, Ali, Sadia, Ren, Xiushui, Whooley, Mary A., and Schiller, Nelson B.

Subjects
Heart Failure, Male, Coronary Artery Disease, Middle Aged, Pulmonary Artery, Article, Echocardiography, Doppler, Pulmonary Valve Insufficiency, Tricuspid Valve Insufficiency, Hospitalization, Cardiovascular Diseases, Predictive Value of Tests, Hypertension, Humans, Female, Aged
Abstract

ObjectivesWe compared the predictive ability of tricuspid regurgitation (TR) and end-diastolic pulmonary regurgitation (EDPR) gradients in outpatients with coronary artery disease.BackgroundThe TR and EDPR gradients, in conjunction with right atrial pressure, provide Doppler estimates of pulmonary artery systolic and diastolic pressures. We hypothesized that increases in TR or EDPR gradients in stable coronary artery disease would predict heart failure (HF) hospitalization or cardiovascular (CV) death.MethodsWe measured TR and EDPR gradients in 717 adults with completed outcome adjudications who were recruited for the Heart and Soul Study. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for HF hospitalization, CV death, all-cause death, and the combined end point. Multivariate adjustments were made for age, gender, race, history of CV or pulmonary disease, functional class, and left ventricular ejection fraction.ResultsThere were 63 HF hospitalizations, 19 CV deaths, and 86 all-cause deaths at the 3-year follow-up. There were 466 measurable EDPR gradients and 573 measurable TR gradients. Age-adjusted ORs for EDPR >5 mm Hg predicted HF hospitalization (2.7, 95% CI 1.3 to 5.5, p = 0.006), all-cause death (2.5, 95% CI 1.4 to 4.4, p = 0.002), and HF hospitalization or CV death (2.7, 95% CI 1.4 to 5.2, p = 0.004). Age-adjusted OR for TR >30 mm Hg predicted HF hospitalization (3.4, 95% CI 1.9 to 6.2, p < 0.0001) and HF hospitalization or CV death (3.0, 95% CI 1.7 to 5.3, p = 0.0001). Multivariate adjusted OR per 5-mm Hg incremental increases in EDPR predicted HF hospitalization or CV death (1.9, 95% CI 1.01 to 3.6, p = 0.046) and all-cause death (1.7, 95% CI 1.05 to 2.8, p = 0.03). Multivariate adjusted OR per 10-mm Hg incremental increases in TR predicted HF hospitalization or CV death (1.6, 95% CI 1.1 to 2.4, p = 0.008).ConclusionsIncreases in EDPR or TR gradients predict HF hospitalization or CV death among ambulatory adults with coronary artery disease.

Full Text
View/download PDF

25. Overwhelming Parasitemia with Plasmodium falciparum Infection in a Patient Receiving Infliximab Therapy for Rheumatoid Arthritis.

Author

Geraghty, Estella M., Ristow, Bryan, Gordon, Shelley M., and Aronowitz, Paul

Subjects
*PLASMODIUM falciparum, *PATIENTS, *RHEUMATOID arthritis, *INFLIXIMAB, *TUMOR necrosis factors, *CYTOKINES, *MALARIA
Abstract

We describe a 45-year-old woman receiving infliximab therapy for rheumatoid arthritis who developed an overwhelming Plasmodium falciparum infection with cerebral malaria. Physicians should be aware that patients receiving tumor necrosis factor inhibitors, such as infliximab, may be at increased risk of life-threatening malarial infections. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results